<code id='7EF1B0EB7D'></code><style id='7EF1B0EB7D'></style>
      • <acronym id='7EF1B0EB7D'></acronym>
      <center id='7EF1B0EB7D'><center id='7EF1B0EB7D'><tfoot id='7EF1B0EB7D'></tfoot></center><abbr id='7EF1B0EB7D'><dir id='7EF1B0EB7D'><tfoot id='7EF1B0EB7D'></tfoot><noframes id='7EF1B0EB7D'>
      • <optgroup id='7EF1B0EB7D'><strike id='7EF1B0EB7D'><sup id='7EF1B0EB7D'></sup></strike><code id='7EF1B0EB7D'></code></optgroup>
        5. <b id='7EF1B0EB7D'><label id='7EF1B0EB7D'><select id='7EF1B0EB7D'><dt id='7EF1B0EB7D'><span id='7EF1B0EB7D'></span></dt></select></label></b><u id='7EF1B0EB7D'></u>
          <i id='7EF1B0EB7D'><strike id='7EF1B0EB7D'><tt id='7EF1B0EB7D'><pre id='7EF1B0EB7D'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / entertainment / explore      
           
     
           
      
          explore 
           
      
           
      
           
       2025-09-29 21:11:33 
   
      
           
      
           
                        
          explore  
          
                                   
                 
                                      author：leisure time   
                                        
                                      
                                      Page View：65367
                                  
                                    
          
                                   
          Adam's take main illustration
          Molly Ferguson/STAT
          Biotech is awash in PIPEs.
          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.
          advertisement
          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study
                                
                            
          Next article：  
                                      
                                          How to save PrEP access — and even expand it
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles